Results 311 to 320 of about 1,594,004 (375)

Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial. [PDF]

J Neurol
Kishnani PS, Díaz-Manera J, Illarioshkin S, van der Ploeg AT, Clemens PR, Day JW, Toscano A, Kushlaf H, Ladha S, Attarian S, Carvalho G, Kostera-Pruszczyk A, Erdem-Özdamar S, Goker-Alpan O, Mozaffar T, Straub V, Roberts M, Haack KA, Huynh-Ba O, Tammireddy S, Periquet M, Thibault N, Zhou T, Dimachkie MM, Schoser B, COMET Investigator Group.   +25 more
europepmc   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Real-World Functional and Anatomic Outcomes With Aflibercept 8.0 mg in Patients With Diabetic Macular Edema. [PDF]

J Vitreoretin Dis
Barbosa GCS, Bala S, Mohan N, Srivastava SK, Kaiser PK, Sastry A, Babiuch AS, Sears J, Talcott KE, Yuan A, Rachitskaya A, Ehlers JP, Schachat AP, Lin P, Sharma S, Mammo DA.   +15 more
europepmc   +1 more source

Imperial strategy of cancer cells through mitochondrial transfer

Molecular Oncology, EarlyView.
Cangkrama et al. demonstrated that cancer cells donate their mitochondria to fibroblasts through mitochondrial transfer, reprogramming them into ‘MitoCAF’. Likewise, our group has identified mitochondrial transfer from cancer cells to tumor infiltrating lymphocytes, resulting in mitochondrial ‘hijack’ and impaired antitumor immunity.
Takamasa Ishino, Yosuke Togashi
wiley   +1 more source

Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors. [PDF]

Invest New Drugs
Wang JS, Arrowsmith ER, Beck JT, Friedmann J, Jamal R, McHale D, Gardner H, Chisamore MJ, Ulahannan SV.   +8 more
europepmc   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Dual Immune Check Point Blockade in <i>MGMT</i>-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. [PDF]

J Clin Oncol
Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP.   +21 more
europepmc   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy. [PDF]

Future Oncol
Grivas P, Tagawa ST, Jain RK, Bupathi M, Balar A, Rezazadeh Kalebasty A, George S, Palmbos P, Nordquist L, Petrylak DP, Davis N, Sternberg CN, Agarwal N, Park C, Tonelli J, Zhou H, Bangs R, Loriot Y.   +17 more
europepmc   +1 more source

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies

Molecular Oncology, EarlyView.
RAS‐targeted therapies have become a clinical reality. Although promising results in patients have been achieved, there are still challenges ahead such as coping with drug resistance. Here we summarize selected RAS inhibitors targeting either individual KRAS mutant isoforms (KRASG12C, KRASG12D, KRASG12V) or exhibiting a wider inhibitory spectrum ...
Matthias Drosten, Mariano Barbacid
wiley   +1 more source